<DOC>
	<DOCNO>NCT03059511</DOCNO>
	<brief_summary>To assess pharmacokinetics parameter nalbuphine intravenous intranasal administration infant . Also effect pain score : Neonatal Infant Pain Score ( NIPS ) safety evaluate summary Adverse Events . Inclusion criterion : Infants 29 days-3 month , minimum Body weight 3.0 kg , Indications : septical work . Exclusion criterion : Infants bear prematurely ( 37 week gestation ) , know kidney liver disease , know chronic illness .</brief_summary>
	<brief_title>Pharmacokinetics Nalbuphine After Intravenous Intranasal Administration Infants</brief_title>
	<detailed_description />
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Infants 29 days3 month Minimum Body weight 3.0 kg Indications : septical work Parent inform study sign Informed Consent Form Infants bear prematurely ( 37 week gestation ) Known kidney liver disease Known chronic illness Documented previous adverse reaction nalbuphine Treatment depressant drug within 5 day prior study Epistaxis , nose trauma ( intranasal application ) Barriere language</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>